MK-677 vs Hexarelin
Both MK-677 and Hexarelin are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.
MK-677
Evidence B+Ibutamoren (MK-677)
An orally active ghrelin-receptor agonist that drives 24-hour increases in GH and IGF-1. Technically a non-peptide small molecule but always grouped with GH peptides.
View full MK-677 profile →Hexarelin
Evidence BHexarelin (HEX)
The strongest GH-releasing hexapeptide and one of the few peptides with documented direct cardiac benefits in animal models. Tachyphylaxis (diminished response over time) limits long-term use.
View full Hexarelin profile →Side-by-Side
| Attribute | MK-677 | Hexarelin |
|---|---|---|
| Evidence Grade | B+ | B |
| FDA Status | Not FDA-approved — investigational (orally active GH secretagogue) | Not FDA-approved — research compound (cardioprotective signals investigated) |
| Typical Dose | 10–25 mg orally, once daily | 100 mcg, 1–2 times daily (subcutaneous) |
| Clinics Indexed | 165 | 41 |
| Categories | growth-hormone, anti-aging | growth-hormone, recovery |
Key reported benefits — MK-677
- ✓Sustained GH/IGF-1 elevation
- ✓Sleep depth
- ✓Lean mass
- ✓Bone density
Key reported benefits — Hexarelin
- ✓Strongest GH spike of GHRPs
- ✓Cardioprotective signals
- ✓Recovery
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.